Zhong Zheng Wang·2025-08-19 12:38Core Insights - Nuo Cheng Jian Hua reported a 74.3% year-on-year revenue growth for the first half of 2025, reaching 730 million yuan, driven by the strong performance of its core product, Obinutuzumab (brand name: Yinuokai), and an upfront payment from a licensing agreement with Prolium [1] - The company's drug revenue increased by 53.5% year-on-year to 640 million yuan, attributed to the inclusion of Obinutuzumab in the national medical insurance and its expanding patient base, particularly in the unique indication of marginal zone lymphoma [1] - The company reduced its losses by 86.7% year-on-year to 36 million yuan in the first half of 2025 [1] Financial Performance - Research and development expenses increased by 6.9% year-on-year to 450 million yuan, primarily for building a differentiated R&D platform and advancing more Phase III clinical projects [1] - As of June 30, 2025, the company held approximately 7.68 billion yuan in cash and cash equivalents, which will support the acceleration of multiple Phase III clinical trials and investments in differentiated ADCs and other pipelines [1] Product Pipeline and Strategic Developments - Nuo Cheng Jian Hua made significant progress in its product pipeline, with Obinutuzumab approved for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and listed as a Level I recommendation in the CSCO lymphoma treatment guidelines [2] - The company’s CD19 monoclonal antibody, Tanshuizhu, in combination with Lenalidomide, was approved for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), marking it as the first CD19 monoclonal antibody approved for this indication in China [2] - The BCL2 inhibitor Mesutoclax (ICP-248) is advancing two registration clinical studies and has received Breakthrough Therapy Designation, making it the first BCL2 inhibitor in China to achieve this status [2] Future Outlook - The CEO of Nuo Cheng Jian Hua stated the company aims to accelerate innovation, commercialization, and internationalization, with plans to advance multiple innovative drugs for approval in the next three to five years and to push three to four products for internationalization [3] - The company is also focused on developing five to ten differentiated molecules in preclinical stages [3]